PaFLO: Pazopanib with 5-fluorouracil, leucovorin, and oxaliplatin (FLO) as first-line treatment in advanced gastric cancer: A randomized phase II study of the  Arbeitsgemeinschaft internistische Onkologie (AIO).

Authors

Kirstin Breithaupt

Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Med Klinik m. S. Hämatologie u. Onkologie, Berlin, Germany

Kirstin Breithaupt , Dmitry Bichev , Mario Lorenz , Daniela Bohnen , Yasemin Dogan , Peter Schlattmann , Salah-Eddin Al-Batran , Markus Hermann Moehler , Peter C. Thuss-Patience

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Final survival results from a multicenter, randomized phase II trial of intravenous paclitaxel plus FOLFOX (ivPOF) and/or intraperitoneal paclitaxel plus FOLFOX (ipPOF) versus mFOLFOX6 as first-line treatment of advanced gastric cancer (AGC): SYLT/FNF 004.

First Author: Shen Zhao

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Pazopanib and 5-FU/oxaliplatin as first-line treatment in advanced gastric cancer: PaFLO, a randomized phase II study from the AIO (Arbeitsgemeinschaft Internistische Onkologie).

First Author: Peter C. Thuss-Patience

insert_chart_outlined

Poster

2022 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC).

First Author: Ryan Sugarman

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study).

First Author: MinKe He